Ocular Toxicity Rare in Patients Taking Hydroxychloroquine

2011 ◽  
Vol 10 (6) ◽  
pp. 48
Author(s):  
SHARON WORCESTER
Keyword(s):  
Ocular Toxicity

scholarly journals Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)

Cancers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 2773
Author(s):  
Marta Padovan ◽  
Marica Eoli ◽  
Alessia Pellerino ◽  
Simona Rizzato ◽  
Claudia Caserta ◽  
...  
Keyword(s):  
Real World ◽  
Recurrent Glioblastoma ◽  
Second Line ◽  
Ocular Toxicity ◽  
Phase 2 ◽  
Second Line Therapy ◽  
Italian Association ◽  
Phase 2 Trial ◽  
Line Therapy ◽  
Ecog Ps

Background: Depatuxizumab Mafodotin (Depatux-M; ABT-414) is an antibody-drug conjugate consisting of a specific antibody against activated EGFR and a cytotoxic agent with antimicrotubule activity. The INTELLANCE 2/EORTC 1410 phase 2 trial produced interesting results for the combination regimen of Depatux-M and temozolomide in EGFR-amplified glioblastoma patients at first recurrence. For the first time worldwide, our work investigated the clinical outcome and safety of this combination in a real-life population. Materials and Methods: Patients were enrolled from seven AINO (Italian Association of Neuro-Oncology) Institutions. The major inclusion criteria were: histologically confirmed diagnosis of glioblastoma, EGFR-amplified, one or more prior systemic therapies and ECOG PS ≤ 2. According to the original schedule, patients received Depatux-M 1.25 mg/kg every 2 weeks combined with temozolomide. The primary endpoints of the study were overall survival and safety. Results: A total of 36 patients were enrolled. The median age was 57 years, ECOG PS was 0–1 in 28 patients (88%), MGMT methylated status was found in 22 (64%), 15 patients (42%) received the combined treatment as second-line therapy. The median OS was 8.04 months (95% CI, 5.3–10.7), the 12 month-OS was 37%. On univariate and multivariate analyses, the MGMT methylation status was the only factor resulting significantly associated with survival. Grade 3 ocular toxicity occurred in 11% of patients; no grade 4 ocular toxicity was reported. No death was considered to be drug-related. Conclusions: The study reported the first “real world” experience of Depatux-M plus temozolomide in recurrent glioblastoma patients. Encouraging clinical benefits were demonstrated, even though most patients were treated beyond second-line therapy. Overall, the results are close to those reported in the previous phase 2 trial. Toxicity was moderate and manageable.

Ocular Toxicity of Targeted Anticancer Agents

Drugs ◽  
2021 ◽  
Author(s):  
Blake H. Fortes ◽  
Prashant D. Tailor ◽  
Lauren A. Dalvin
Keyword(s):  
Anticancer Agents ◽  
Ocular Toxicity

Selected Aspects of Ocular Toxicity Studies With a Focus on High-Quality Pathology Reports: A Pathology/Toxicology Consultant’s Perspective

2020 ◽  
pp. 019262332094671
Author(s):  
Brian Short
Keyword(s):  
Species Selection ◽  
Toxicity Study ◽  
Pathology Report ◽  
Ocular Toxicity ◽  
High Quality ◽  
Contract Research Organization ◽  
Toxicity Studies ◽  
Fit For Purpose ◽  
Pathology Reports ◽  
Study Designs

Ocular toxicity studies are the bedrock of nonclinical ocular drug and drug–device development, and there has been an evolution in experience, technologies, and challenges to address that ensures safe clinical trials and marketing authorization. The expectations of a well-designed ocular toxicity study and the generation of a coherent, integrative ocular toxicology report and subreports are high, and this article provides a pathology/toxicology consultant’s perspective on achieving that goal. The first objective is to cover selected aspects of study designs for ocular toxicity studies including considerations for contract research organization selection, minipig species selection, unilateral versus bilateral dosing, and in-life parameters based on fit-for-purpose study objectives. The main objective is a focus on a high-quality ocular pathology report that includes ocular histology procedures to meet regulatory expectations and a report narrative and tables that correlate microscopic findings with key ophthalmic findings and presents a clear interpretation of test article-, vehicle-, and procedure-related ocular and extraocular findings with identification of adversity and a pathology peer review. The last objective covers considerations for a high-quality ophthalmology report, which in concert with a high-quality pathology report, will pave the way for a best quality toxicology report for an ocular toxicity study.

Liposome-encapsulated mitomycin C for the reduction of corneal healing rate and ocular toxicity

2007 ◽  
Vol 17 (1) ◽  
pp. 43-48 ◽  
Author(s):  
P. Chetoni ◽  
S. Burgalassi ◽  
D. Monti ◽  
M. Najarro ◽  
E. Boldrini
Keyword(s):  
Mitomycin C ◽  
Healing Rate ◽  
Ocular Toxicity

Prevention of Ocular Toxicity of Carmustine (BCNU) with Supraophthalmic Intracarotid Infusion

Ophthalmology ◽  
1986 ◽  
Vol 93 (11) ◽  
pp. 1471-1475 ◽  
Author(s):  
Georgia Antonakou Chrousos ◽  
Edward H. Oldfield ◽  
John L. Doppman ◽  
David G. Cogan
Keyword(s):  
Ocular Toxicity

Ocular toxicity studies with zinc pyridinethione

1978 ◽  
Vol 45 (3) ◽  
pp. 771-782 ◽  
Author(s):  
G.G. Cloyd ◽  
M. Wyman ◽  
J.A. Shadduck ◽  
M.J. Winrow ◽  
G.R. Johnson
Keyword(s):  
Ocular Toxicity ◽  
Toxicity Studies

Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues

2018 ◽  
Vol 29 (6) ◽  
pp. 645-653 ◽  
Author(s):  
Ammar El Ameen ◽  
Guillaume Vandermeer ◽  
Raoul K Khanna ◽  
Pierre-Jean Pisella
Keyword(s):  
Intraocular Pressure ◽  
Prostaglandin Analogue ◽  
Ocular Toxicity ◽  
Prostaglandin Analogues ◽  
Conjunctival Hyperaemia ◽  
Ocular Symptoms ◽  
Tear Meniscus ◽  
Tear Meniscus Height ◽  
Preservative Free ◽  
Ocular Signs

Purpose: Preservatives in glaucoma medications have been associated with ocular toxicity. We compared ocular signs and symptoms in patients with open-angle glaucoma or ocular hypertension treated in monotherapy with preserved or preservative-free prostaglandin analogues. Methods: Observational cross-sectional clinical study in real life. 82 patients treated for at least 6 months with prostaglandin analogue were assessed for intraocular pressure, ocular symptoms and ocular signs including conjunctival hyperaemia, tear break-up time and tear meniscus height measured using objective and non-invasive methods (OCULUS Keratograph 5M). Patients presenting with symptoms of ocular toxicity with preserved prostaglandin analogues were switched to preservative-free latanoprost, and a second assessment was processed 6 months after. Results: At inclusion, 30 (36.6%) patients were treated with preservative-free latanoprost, 25 (30.5%) with preserved latanoprost, 16 (19.5%) with preserved travoprost and 11 (13.4%) with preserved bimatoprost. Patients treated with preservative-free latanoprost reported significantly less ocular symptoms upon instillation (mainly burning) and between instillations than patients treated with preserved prostaglandin analogues. The mean conjunctival hyperaemia (limbal + bulbar) was significantly lower with preservative-free latanoprost (2.08 ± 0.55) compared to preserved latanoprost (2.50 ± 0.7, p = 0.0085), preserved travoprost (2.67 ± 0.82, p = 0.0083) and preserved bimatoprost (2.68 ± 0.67, p = 0.0041). There were no relevant between-group differences in mean tear meniscus height and break-up time. Ocular symptoms and conjunctival hyperaemia improved when preserved prostaglandin analogues were switched to preservative-free latanoprost for 6 months while intraocular pressure reduction was maintained. Conclusion: Overall, this study suggests a better subjective and objective ocular tolerance when patients were treated with preservative-free latanoprost than with other preserved prostaglandin analogues monotherapy. Switching to preservative-free latanoprost maintained intraocular pressure at the same level as preservative prostaglandin analogue, but improved ocular surface tolerance.

Sign in / Sign up

Export Citation Format

Share Document